Parkinson’s Disease & Polygraph Testing: Examiner Guide

What Examiners Need to Know About PD Pathology

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopamine-producing neurons in the substantia nigra, a region of the midbrain critical to motor control [1]Verified Global burden of Parkinson's disease from 1990 to 2021: a population-based study
Confirms PD is the second most prevalent neurodegenerative illness and provides global epidemiological trend data from GBD 2021. PD is the second most common neurodegenerative illness worldwide [2]Verified Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021
Confirms 11.77 million people worldwide had Parkinson's disease in 2021 based on GBD Study 2021, and according to the Global Burden of Disease Study 2021, approximately 11.77 million people worldwide were living with PD in 2021 [3]Verified Statistics - Parkinson's Foundation
Confirms more than 10 million people worldwide are estimated to be living with PD, with 1.1 million in the U.S. — a figure that the Parkinson's Foundation corroborates at over 10 million [4]Verified Global, regional, and national burden of Parkinson's disease, 1990–2016: GBD Study 2016
Confirms the global burden of PD more than doubled over a generation with 6.1 million cases in 2016. The global burden has more than doubled over the past generation [5]Verified Cases of Parkinson's disease set to reach 25 million worldwide by 2050
Confirms projection of 25.2 million PD cases by 2050, a 112% increase from 2021, and cases are projected to reach 25.2 million by 2050, a 112% increase driven largely by population ageing [6]Verified The pathophysiology of Parkinson's disease tremor
Confirms PD tremor occurs in 75% of patients, is classically at rest at 4-6 Hz frequency.

The hallmark motor symptoms include resting tremor (typically beginning unilaterally and manifesting as a "pill-rolling" motion of the fingers at a characteristic frequency of 4-6 Hz [7]Verified Prevalence and clinical aspects of depression in Parkinson's disease: A systematic review and meta-analysis of 129 studies
Confirms the prevalence of depression in PD was 38% by meta-analysis of 129 studies with 38,304 participants), bradykinesia (slowness of movement), rigidity (increased muscle tone), and postural instability. Tremor occurs in roughly 75% of PD patients and is often present at disease onset [7]Verified Prevalence and clinical aspects of depression in Parkinson's disease: A systematic review and meta-analysis of 129 studies
Confirms the prevalence of depression in PD was 38% by meta-analysis of 129 studies with 38,304 participants. These motor symptoms result from dopamine depletion in the basal ganglia, disrupting the normal signalling pathways that allow smooth, coordinated voluntary movement.

However, the non-motor symptoms of PD are often more consequential for polygraph testing than the motor symptoms. These include autonomic nervous system dysfunction (affecting heart rate regulation, blood pressure control, sweating, and gastrointestinal function), cognitive changes (executive function deficits, slowed processing speed, and in advanced cases, dementia), psychiatric symptoms (depression affects approximately 35-40% of PD patients [8]Verified Depression, with an estimated prevalence of about 40%, in Parkinson disease
Confirms depression prevalence of approximately 40% in Parkinson disease[9]Verified Hoehn and Yahr Scale - Modified
Confirms the Hoehn and Yahr scale was published in 1967 with stages 1-5, later modified to include stages 1.5 and 2.5, anxiety, apathy, and in some cases, psychosis), and sleep disturbances (insomnia, REM sleep behaviour disorder, and excessive daytime sleepiness). Examiners familiar with anxiety disorders and polygraph testing will recognise that PD-related anxiety adds a further layer of complexity.

The Hoehn and Yahr Staging System

Parkinson's disease progression is classified using the Hoehn and Yahr scale, originally published in 1967 by Margaret Hoehn and Melvin Yahr [10]Verified Autonomic Dysfunction in Parkinson's Disease
Confirms 71% of Stage 1 PD patients had autonomic symptoms at baseline, rising to 100% at 3 years. The scale ranges from Stage 1 through Stage 5 and is used globally to describe how motor symptoms progress [10]Verified Autonomic Dysfunction in Parkinson's Disease
Confirms 71% of Stage 1 PD patients had autonomic symptoms at baseline, rising to 100% at 3 years. Understanding where an examinee falls on this scale is critical for assessing testing feasibility.

Stage 1 — Unilateral Involvement: Symptoms affect only one side of the body. Tremor is typically mild and the individual functions independently. One study of 112 patients at Hoehn & Yahr Stage 1 found that at least one autonomic symptom was already present in 71% at baseline [11]Verified Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times
Confirms median transition time from H&Y Stage 1 to 2 was 20 months in a study of 695 patients. Polygraph testing is generally feasible at this stage with standard accommodations.

Stage 2 — Bilateral Involvement Without Balance Impairment: Symptoms are present on both sides. Walking and balance remain intact, but daily tasks may take longer. Tremor may be more prominent and early autonomic symptoms may emerge. Polygraph testing is often feasible but requires careful pre-test assessment.

Stage 3 — Moderate Disease with Postural Instability: Balance impairment becomes clinically significant. Motor symptoms are moderate to severe and autonomic dysfunction is often well established. Polygraph data quality becomes increasingly compromised. Testing feasibility must be evaluated case by case.

Stage 4 — Severe Disability: The individual requires substantial assistance. Motor symptoms are severe, medication effectiveness may be inconsistent ("on-off" fluctuations), and autonomic dysfunction is typically pronounced. Polygraph testing is generally not recommended.

Stage 5 — Wheelchair-Bound or Bedridden: The most advanced stage. Full-time care is required. Motor and autonomic symptoms are severe, and cognitive impairment is common. Polygraph testing is contraindicated.

The progression from Stage 1 to Stage 5 can span years to decades, and the rate varies significantly between individuals. A study of 695 patients found that the median time to transit from Stage 1 to Stage 2 was 20 months [12]Verified EDA Primer for Polygraph Examiners
Confirms electrodermal response is the most robust and informative signal in polygraph testing, driven exclusively by sympathetic nervous system activity. Importantly, the severity of non-motor symptoms (particularly autonomic dysfunction) does not always correlate with the motor stage, meaning some individuals with relatively mild motor symptoms may still have significant autonomic impairment affecting polygraph data quality.

Electrodermal Activity (EDA) / Galvanic Skin Response (GSR)

The electrodermal activity channel is arguably the most affected by Parkinson's disease. Research has established that the EDA measurement is driven exclusively by sympathetic nervous system activity, making it the most robust and informative signal in polygraph testing [13]Verified Sweating dysfunction in Parkinson's disease
Confirms sweating disturbances were reported by 64% of PD patients vs 12.5% of controls, and problems occurred mainly during off periods. In PD patients, however, this sympathetic system is frequently impaired.

Sweating disturbances — either hypohidrosis or hyperhidrosis — were reported by 64% of PD patients in a landmark study by Swinn et al., compared to just 12.5% of controls [14]Verified Sweating and other thermoregulatory abnormalities in Parkinson's disease
Confirms prevalence of sweating abnormalities ranges from 5.5% in newly diagnosed patients to up to 64% in later stages. The prevalence of sweating abnormalities ranges from approximately 5.5% in newly diagnosed patients to up to 64% during later stages [15]Verified Sudomotor deficits in Parkinson's disease with special reference to motor subtypes
Confirms thermal anhidrosis in 70.9% of 225 PD patients, with tremor-dominant type showing least deficits. A study of 225 PD patients found thermal anhidrosis of varying degree in 70.9% of patients, with the akinesia-rigidity subtype showing the most significant deficits [16]Verified Relative Accuracy of Polygraph Examiner Diagnosis of Respiration, Blood Pressure, and GSR Recordings
Confirms electrodermal (GSR) measures provided the most diagnostic information, followed by cardiovascular and respiratory channels.

Hypohidrosis (reduced sweating), particularly in the distal extremities where EDA sensors are placed, reduces sweat gland responsiveness. This produces flattened, non-reactive EDA tracings that can closely resemble the patterns sometimes associated with truthful responding — creating a risk of false negative results. Field research has confirmed that electrodermal measures provide the most diagnostic information in polygraph scoring [17]Verified Hyperhidrosis in Parkinson's disease
Confirms axial hyperhidrosis in PD could be compensatory for reduced sympathetic function in extremities, making this channel's compromise especially significant.

Hyperhidrosis (excessive sweating) affects some PD patients as a compensatory mechanism. Research suggests that axial hyperhidrosis could be a compensatory phenomenon for reduced sympathetic function in the extremities [18]Verified Prevalence and incidence of orthostatic hypotension in Parkinson's disease: updated systematic review and meta-analysis
Confirms pooled OH prevalence of 33% from 55 studies involving 10,463 PD patients, with neurogenic subtype at 26%, which can elevate baseline conductance and create erratic EDA data. Additionally, the rhythmic 4-6 Hz oscillation of PD resting tremor can create periodic fluctuations in sensor contact pressure, producing artifacts that might be confused with legitimate electrodermal responses. For a deeper understanding of EDA principles, see the foundational EDA primer for polygraph examiners by Handler and Nelson [13]Verified Sweating dysfunction in Parkinson's disease
Confirms sweating disturbances were reported by 64% of PD patients vs 12.5% of controls, and problems occurred mainly during off periods.

Cardiovascular Channel (Cardio Cuff / Plethysmograph)

Parkinson's disease affects cardiovascular polygraph recordings through multiple mechanisms. Cardiovascular autonomic dysfunction in PD includes orthostatic hypotension (OH), which a comprehensive meta-analysis of 55 studies involving 10,463 patients estimated at a pooled prevalence of 33% [19]Verified Orthostatic Hypotension in Parkinson Disease
Confirms 30-50% cross-sectional OH prevalence in PD, with only 16% symptomatic. Individual studies report cross-sectional prevalence of 30-50% [20]Verified Stages of Parkinson's - Parkinson's Foundation
Confirms Hoehn & Yahr defined five stages in 1967 and that motor fluctuations can become an issue 5-10 years after diagnosis, with only about 16% of patients experiencing symptomatic OH [20]Verified Stages of Parkinson's - Parkinson's Foundation
Confirms Hoehn & Yahr defined five stages in 1967 and that motor fluctuations can become an issue 5-10 years after diagnosis. These figures increase with age and disease duration [19]Verified Orthostatic Hypotension in Parkinson Disease
Confirms 30-50% cross-sectional OH prevalence in PD, with only 16% symptomatic.

For polygraph purposes, these cardiovascular changes create several challenges. Baseline instability means blood pressure and heart rate may drift unpredictably during testing, making it difficult to establish a stable baseline. Reduced cardiovascular reactivity means the sympathetically mediated blood pressure increases and heart rate accelerations that typically accompany deceptive responses may be blunted or absent. Positional sensitivity means even minor postural shifts can trigger disproportionate cardiovascular responses due to impaired baroreceptor function. Upper extremity tremor can also transmit vibrations through the arm to the cardio cuff, creating oscillatory noise.

These cardiovascular effects are particularly concerning because research has shown the cardiovascular channel to be one of the most reliable indicators in polygraph scoring, alongside the electrodermal channel [17]Verified Hyperhidrosis in Parkinson's disease
Confirms axial hyperhidrosis in PD could be compensatory for reduced sympathetic function in extremities. Understanding the four components of a polygraph helps examiners appreciate why multi-channel compromise in PD is so problematic.

Pneumograph (Respiratory) Channel

Respiratory function in Parkinson's disease is affected by both motor symptoms and autonomic dysfunction. The pneumograph tubes measure thoracic and abdominal respiratory excursion, and PD can compromise these readings in several ways.

Chest wall rigidity — a cardinal motor symptom of PD — reduces thoracic excursion, creating a characteristic shallow, rapid breathing pattern that differs from normal respiratory baselines. Some PD patients exhibit respiratory dysrhythmia, including irregular breathing patterns, periodic obstructive episodes, and involuntary sighing or gasping that can mimic the respiratory suppression or changes examiners look for during deception.

In patients experiencing levodopa-induced dyskinesias (involuntary writhing or jerking movements), trunk movements can directly displace the pneumograph tubes, creating false respiratory excursion data. Some PD patients also have difficulty following instructions to breathe normally — not due to non-compliance, but due to the motor control deficits inherent to the disease.

Examiners should note that research into individual channel diagnostic accuracy has found that respiratory recordings, while valuable, provide less diagnostic information than electrodermal or cardiovascular channels [17]Verified Hyperhidrosis in Parkinson's disease
Confirms axial hyperhidrosis in PD could be compensatory for reduced sympathetic function in extremities. When respiratory data from PD examinees is compromised, the examiner should weight remaining channels accordingly in their analysis.

Movement Sensor Channel

If the polygraph instrument includes a seat sensor or movement detection pad, Parkinson's disease creates significant challenges. Resting tremor, postural adjustments to maintain balance, dyskinesias, and the general motor restlessness common in PD will all register as movement artifacts.

In most cases, the movement channel in a PD examinee will show near-constant activity, making it difficult to distinguish between disease-related movement and deliberate countermeasure attempts. This has an important secondary implication: examiners cannot reliably use movement sensor data to detect countermeasure attempts in PD examinees, since the involuntary movement baseline is already elevated. This eliminates one of the examiner's quality assurance tools during testing.

For examiners working in contexts such as PCSOT programs, this limitation should be clearly documented in pre-test notes and factored into the overall assessment of data quality.

Major Drug Classes and Their Effects

The pharmacological management of Parkinson's disease involves medications that directly affect the neurotransmitter systems governing polygraph-relevant physiology. Every examiner conducting a pre-test assessment must understand how each major drug class affects physiological data channels. For a broader overview, consult our complete guide to polygraph testing.

Levodopa / Carbidopa (Sinemet): This is the primary PD medication, replacing depleted dopamine. It can cause blood pressure fluctuations (both hypotension and hypertension), excessive sweating or altered sudomotor function, and "on-off" phenomena that create variable physiology throughout the day. Dyskinesias during "on" periods create movement artifacts across all channels.

Dopamine Agonists (Pramipexole, Ropinirole): These mimic dopamine at receptor sites. They carry significant orthostatic hypotension risk, may cause drowsiness and fatigue (affecting alertness), can alter emotional processing and reward circuits, and in some patients cause impulse control disorders that may affect response patterns.

Anticholinergic Agents (Benztropine, Trihexyphenidyl): These block acetylcholine to reduce tremor but directly suppress eccrine sweat gland activity — which is critical for EDA measurement. They cause dry mouth, blurred vision, and constipation, and may impair cognitive function and attention. This is the most problematic medication class for polygraph EDA data.

Beta-Blockers (Propranolol) and MAO-B Inhibitors: Beta-blockers are sometimes used adjunctively for tremor and directly dampen cardiovascular reactivity (heart rate and blood pressure). MAO-B inhibitors (selegiline, rasagiline) have stimulant metabolites. Amantadine may cause livedo reticularis and peripheral oedema. COMT inhibitors can enhance levodopa effects and side effects.

The On-Off Phenomenon and Testing Timing

The "on-off" phenomenon deserves special attention from polygraph examiners. As PD progresses, many patients on levodopa therapy experience fluctuations — periods when medication works well ("on" state) followed by periods when symptoms return or worsen ("off" state). Motor fluctuations can become an issue five to ten years after diagnosis [21]Verified Federal Psychophysiological Detection of Deception Examiner Handbook
Official policy manual for federal polygraph programs with standardized testing procedures, scoring methods, and quality assurance requirements.

During "on" periods, the patient may have relatively well-controlled tremor but may experience dyskinesias and more active autonomic fluctuations. During "off" periods, tremor and rigidity may be prominent, but autonomic parameters may be more stable (though baseline physiology may still be abnormal). Sweating problems have been documented to occur predominantly during off periods and during on periods with dyskinesias [14]Verified Sweating and other thermoregulatory abnormalities in Parkinson's disease
Confirms prevalence of sweating abnormalities ranges from 5.5% in newly diagnosed patients to up to 64% in later stages.

For polygraph purposes, testing should ideally be conducted during the peak medication effectiveness window — typically 1-2 hours after the most recent levodopa dose — when motor symptoms are best controlled while autonomic effects are not yet at their peak. This represents a narrow window, and the examiner must coordinate timing carefully with the examinee.

Examiners should never ask an examinee to alter their medication regimen for testing purposes. Doing so could pose serious health risks and would be both unethical and potentially illegal. The examiner's role is to work within the examinee's existing medical management, consistent with the ethical standards outlined in the Federal Psychophysiological Detection of Deception Examiner Handbook [22]Verified Epidemiology of autonomic dysfunction in Parkinson's disease (Review)
Confirms autonomic dysfunction symptoms in 70-90% of PD patients, OH prevalence of 30-50%, and GU dysfunction in 89%.

The Core Challenge for Polygraph Validity

Autonomic dysfunction represents the single most significant challenge that Parkinson's disease poses to polygraph validity. The polygraph instrument fundamentally measures autonomic nervous system reactivity — the sympathetic activation that accompanies stress, anxiety, and the cognitive load associated with deception. When the autonomic nervous system itself is damaged, the physiological basis of polygraph testing is directly affected.

Research consistently demonstrates that autonomic dysfunction symptoms are reported by 70-90% of PD patients, though they are frequently under-recognised [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort. A large Chinese multicentre cohort study of 2,556 PD patients found that 91.28% had autonomic dysfunction [24]Verified Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment
Confirms autonomic dysfunction as an essential non-motor phenotype in PD, with constipation, OH and urinary dysfunction as prodromal markers. Even at the earliest disease stages, autonomic impairment is already present — a study of 112 patients at Hoehn & Yahr Stage 1 found at least one autonomic symptom in 71% at baseline, rising to 100% three years later [11]Verified Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times
Confirms median transition time from H&Y Stage 1 to 2 was 20 months in a study of 695 patients.

In PD, autonomic dysfunction arises from the degeneration of both central and peripheral autonomic neurons. The Lewy body pathology (abnormal alpha-synuclein protein aggregates) that characterises PD is not limited to the substantia nigra — it affects autonomic centres in the brainstem, hypothalamus, spinal cord, and peripheral autonomic ganglia [25]Verified Sudomotor dysfunction in Parkinson's disease
Confirms sudomotor dysfunction primarily affects distal extremities in PD, with reduced sweating in hands and feet. Research confirms that dysautonomia often precedes motor symptoms [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort, meaning that even newly diagnosed PD patients may have substantial autonomic impairment.

Specific Autonomic Domains Affecting Polygraph Data

Cardiovascular autonomic dysfunction: An updated meta-analysis of 55 studies involving 10,463 PD patients found a pooled prevalence of orthostatic hypotension of 33% [19]Verified Orthostatic Hypotension in Parkinson Disease
Confirms 30-50% cross-sectional OH prevalence in PD, with only 16% symptomatic, with the neurogenic subtype accounting for 26%. The prevalence of asymptomatic OH is substantial at 22% [19]Verified Orthostatic Hypotension in Parkinson Disease
Confirms 30-50% cross-sectional OH prevalence in PD, with only 16% symptomatic, which is particularly relevant for polygraph testing because examinees may not report cardiovascular symptoms they are unaware of. Supine hypertension affects 34-50% of PD patients [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort, and non-dipping blood pressure patterns occur in 83-88% [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort. For the polygraph, this means the cardiovascular channel may show attenuated or unstable responses regardless of truthfulness.

Sudomotor dysfunction: Sweating disturbances affect up to 64% of PD patients [14]Verified Sweating and other thermoregulatory abnormalities in Parkinson's disease
Confirms prevalence of sweating abnormalities ranges from 5.5% in newly diagnosed patients to up to 64% in later stages, with the prevalence increasing substantially with disease stage [15]Verified Sudomotor deficits in Parkinson's disease with special reference to motor subtypes
Confirms thermal anhidrosis in 70.9% of 225 PD patients, with tremor-dominant type showing least deficits. Research using thermal sweating tests demonstrated that thermoregulatory sweating deficits primarily affect the distal extremities [16]Verified Relative Accuracy of Polygraph Examiner Diagnosis of Respiration, Blood Pressure, and GSR Recordings
Confirms electrodermal (GSR) measures provided the most diagnostic information, followed by cardiovascular and respiratory channels[26]Verified Sweating dysfunction in PD - APDA
Confirms sweating dysfunction is being investigated as a biomarker of PD and that Parkinson's excessive sweating tends to occur on face, head, and trunk — precisely where EDA sensors are placed. Sudomotor dysfunction is being actively investigated as a potential diagnostic biomarker for PD [27]Verified Advances in autonomic dysfunction research in Parkinson's disease
Confirms 70-80% of PD patients may suffer from gastrointestinal autonomic dysfunction, and 30-50% experience OH. This can produce hyporesponsive or flat EDA tracings, undermining the most diagnostically valuable polygraph channel [13]Verified Sweating dysfunction in Parkinson's disease
Confirms sweating disturbances were reported by 64% of PD patients vs 12.5% of controls, and problems occurred mainly during off periods.

Gastrointestinal autonomic dysfunction: While not directly measured by the polygraph, GI symptoms are extremely common — 70-80% of patients may suffer from gastrointestinal autonomic dysfunction [28]Verified Examiner Approach and its Impact on Polygraph Results
Confirms interrogative examiner approaches compromise polygraph validity and can lead to false positives, with constipation observed during the prodromal period in 60% and in up to 100% over the disease course [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort. These symptoms can cause physical discomfort during testing that introduces non-deception-related physiological responses.

Urinary autonomic dysfunction: Genitourinary dysfunction affects approximately 89% of PD patients [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort. Bladder urgency and frequency may require more frequent breaks during testing and can cause discomfort-related physiological artifacts if not managed.

The practical implication for polygraph examiners is significant: if the autonomic nervous system cannot generate normal physiological responses to relevant stimuli, the absence of a response cannot be interpreted as indicating truthfulness, and the presence of a response may be caused by disease-related autonomic instability rather than deception. This is analogous to challenges seen in our guide on schizophrenia and lie detector tests, where neurological conditions disrupt the physiological assumptions underlying polygraph scoring.

Building an Informed Assessment

A thorough pre-test medical assessment is the foundation of responsible polygraph testing for any examinee with Parkinson's disease. This assessment must go beyond the standard pre-test interview to gather specific information about the examinee's disease status, medication regimen, and functional capabilities. The goal is to make an informed determination about testing feasibility before attaching any sensors.

The principle of informed consent takes on additional importance when testing individuals with medical conditions. The examinee must understand that their condition may affect test results, that the examiner may need to terminate testing if data quality is insufficient, and that any limitations will be documented in the report. Examiner approach significantly impacts polygraph outcomes [29]Verified Reliability of the Empirical Scoring System with expert examiners
Confirms substantial inter-rater agreement (Fleiss kappa.61) and 95.4% mean decision agreement among expert examiners, making a compassionate and well-informed pre-test interaction essential.

Gather Diagnostic Information: Ask about the date of diagnosis, the diagnosing physician, the current disease stage (if known), and the general trajectory of symptom progression. Determine whether the examinee has been evaluated by a movement disorder specialist, as this suggests a more thoroughly characterised disease state.

Complete Medication Inventory: Document every medication the examinee is taking, including name, dosage, frequency, and the time of the most recent dose. Pay particular attention to levodopa/carbidopa timing, anticholinergic agents, beta-blockers, and any psychiatric medications used to manage PD-related mood symptoms. Note the examinee's typical "on" and "off" patterns.

Assess Motor Symptoms: Observe the examinee's current motor state. Note the presence, severity, and distribution of tremor (unilateral vs. bilateral, resting vs. action), rigidity, bradykinesia, and any dyskinesias. Assess whether the examinee can sit comfortably in a standard chair for the expected test duration.

Screen for Autonomic Dysfunction: Ask specifically about episodes of lightheadedness upon standing (indicating OH), sweating abnormalities, urinary urgency or frequency, and any recent changes in blood pressure management. Given that autonomic dysfunction prevalence is 70-90% in PD [23]Verified Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study
Confirms 91.28% of 2,556 PD patients had autonomic dysfunction in a large multicenter cohort, assume some degree of autonomic impairment is present.

Evaluate Cognitive Status: Screen for cognitive impairment that could affect the examinee's ability to understand test questions, follow instructions, and provide reliable verbal responses. Depression affects approximately 35-40% of PD patients [8]Verified Depression, with an estimated prevalence of about 40%, in Parkinson disease
Confirms depression prevalence of approximately 40% in Parkinson disease[9]Verified Hoehn and Yahr Scale - Modified
Confirms the Hoehn and Yahr scale was published in 1967 with stages 1-5, later modified to include stages 1.5 and 2.5 and can independently influence physiological reactivity, compounding the challenges. This overlaps with considerations in ADHD and polygraph testing where cognitive factors also play a role.

Optimising Conditions for PD Examinees

When testing is deemed feasible, specific accommodations can improve data quality and examinee comfort. These modifications should be documented in the test report.

Timing and Scheduling: Schedule the examination during the examinee's peak medication window, typically 1-2 hours after their most recent levodopa dose. Avoid scheduling during times when the examinee reports their symptoms are typically worst. Morning appointments are often preferred, as fatigue tends to worsen throughout the day.

Sensor Placement and Stabilisation: Secure EDA finger plates firmly but comfortably to minimise motion artifact from tremor. Consider using the least affected hand for EDA placement. Ensure the cardio cuff is positioned on the arm with less tremor. Use additional tape or stabilisation for pneumograph tubes if trunk dyskinesia is present.

Environmental Control: Maintain a comfortable room temperature, as PD patients often have impaired thermoregulation. Minimise distracting noises and visual stimuli. Ensure the testing chair provides adequate support and comfort — armrests may help stabilise tremor.

Test Protocol Modifications: Allow more frequent rest breaks to manage fatigue and address bladder urgency. Extend inter-question intervals to allow physiology to return to baseline between questions, as autonomic recovery may be slower in PD. Consider using shorter test formats if sustained attention is a concern. The examiner should be prepared to modify or terminate testing if data quality deteriorates.

Examiners should apply the same rigorous scoring methods validated in reliability research [30]Verified The Reliability of Polygraph Examiner Diagnosis of Truth and Deception
Foundational research demonstrating high inter-rater reliability for experienced examiners using structured scoring methods[31]Verified The Accuracy and Consistency of Polygraph Examiners' Diagnoses
Confirms examiner accuracy of 92.4% for deceptive subjects and 95.5% for truthful subjects with structured scoring, while remaining alert to the specific artifacts and patterns that PD introduces across channels.

Identifying PD-Specific Artifacts and Scoring Considerations

Recognising PD-specific artifacts is essential for accurate scoring. Tremor artifacts typically present as rhythmic oscillations at the characteristic 4-6 Hz frequency [7]Verified Prevalence and clinical aspects of depression in Parkinson's disease: A systematic review and meta-analysis of 129 studies
Confirms the prevalence of depression in PD was 38% by meta-analysis of 129 studies with 38,304 participants and may be visible across multiple channels simultaneously. These differ from the aperiodic, stimulus-locked physiological responses that examiners evaluate during scoring.

On the EDA channel, tremor artifacts appear as regular, repeating waveforms that do not correlate with question timing. Genuine electrodermal responses are stimulus-locked, appearing within 1-3 seconds of question onset. If apparent EDA responses coincide with visible tremor activity noted by the examiner, they should be regarded as artifacts.

On the cardiovascular channel, PD-related baseline drift and tremor-transmitted oscillations must be distinguished from stimulus-evoked blood pressure and heart rate changes. Compare any apparent cardiovascular responses with the timing of questions and with activity on other channels.

For scoring purposes, examiners should apply structured scoring methods that have demonstrated high inter-rater reliability [30]Verified The Reliability of Polygraph Examiner Diagnosis of Truth and Deception
Foundational research demonstrating high inter-rater reliability for experienced examiners using structured scoring methods[32]Verified Resting and action tremor in Parkinson's disease: pathophysiological insights from long-term STN-DBS
Confirms DBS treatment for PD tremor and that resting tremor responded better to L-Dopa and STN-DBS than action tremor. If one or more channels are deemed unreliable due to PD interference, the examiner should note which channels were excluded from scoring and explain why. A well-documented inconclusive result is always preferable to an unreliable diagnostic call.

Understanding the diagnostic impression in a polygraph report is particularly important in these cases, as the examiner's professional opinion must account for the medical complexities present.

Recognising When Testing Should Not Proceed

There are circumstances where testing a PD examinee would be inappropriate and the examiner should decline to proceed. A well-documented declination is a professional act that protects the examinee, the examiner, and the integrity of the polygraph profession.

Clear contraindications include: Hoehn & Yahr Stage 4-5 disease, where motor and autonomic impairment is typically too severe for reliable data collection. Significant cognitive impairment or dementia, which compromises the examinee's ability to understand and follow test protocols. Severe autonomic failure with documented orthostatic hypotension requiring pharmacological management. Active psychosis or severe psychiatric symptoms. Inability to sit comfortably for the minimum test duration. Multiple anticholinergic medications that would render EDA data unreliable.

Relative contraindications requiring careful case-by-case evaluation include: Stage 3 disease with moderate autonomic dysfunction. Significant medication-related fluctuations (severe on-off phenomenon). Moderate cognitive impairment. Severe depression or anxiety requiring multiple psychiatric medications.

When declining to test, document the clinical rationale thoroughly. Include the examinee's disease stage, observed motor symptoms, medication regimen, and the specific physiological concerns that led to the decision. This documentation serves legal and professional purposes and should reflect the same standards required by federal polygraph programmes [22]Verified Epidemiology of autonomic dysfunction in Parkinson's disease (Review)
Confirms autonomic dysfunction symptoms in 70-90% of PD patients, OH prevalence of 30-50%, and GU dysfunction in 89%.

DBS-Specific Challenges for Examiners

Deep brain stimulation (DBS) is an increasingly common surgical treatment for PD, involving the implantation of electrodes that deliver electrical stimulation to targeted brain regions, typically the subthalamic nucleus [33]Verified Main Features of Polygraph Examiners Training
Identifies core elements essential for effective polygraph examiner training programs, relevant to medical condition curriculum. DBS can significantly reduce tremor and motor symptoms, but it introduces unique considerations for polygraph testing.

No published research currently addresses polygraph testing specifically in DBS patients. However, examiners should consider several factors. DBS devices generate electrical signals that could theoretically interfere with sensitive polygraph sensors, particularly EDA equipment. The presence of DBS may alter autonomic function in unpredictable ways, as stimulation of the subthalamic nucleus can affect non-motor circuits. DBS may reduce tremor artifacts (a potential benefit for data quality) while simultaneously altering the neural processing of emotional and cognitive stimuli.

Examiners encountering a DBS patient should consult with the examinee's neurologist about device settings and any known autonomic effects. The same staging and assessment principles apply, but with the additional consideration that DBS alters the neurological landscape in ways not yet studied in a polygraph context. This represents an area where future research is needed, similar to how the field has developed understanding of sociopathy, psychopathy and polygraph testing over time.

Professional Responsibilities When Testing Medically Complex Examinees

Testing examinees with Parkinson's disease raises important ethical obligations that go beyond standard polygraph practice. The examiner must balance the requesting party's legitimate need for information against the examinee's right to a fair and scientifically sound examination.

Informed consent must be thoroughly documented. The examinee should understand that their condition may affect test results, that testing may be terminated if data quality is insufficient, and that any limitations will be reported. Research has demonstrated that examiner approach significantly impacts polygraph validity [29]Verified Reliability of the Empirical Scoring System with expert examiners
Confirms substantial inter-rater agreement (Fleiss kappa.61) and 95.4% mean decision agreement among expert examiners, and an interrogative approach aimed at extracting confessions rather than diagnostic truth assessment can compromise results — a risk heightened when medical conditions are present.

Examiners should never represent PD-compromised test results as having the same validity as results from unimpaired examinees. When reporting, clearly state the medical conditions present, the accommodations made, and any limitations on data interpretation. The polygraph history timeline shows how the field has progressively embraced higher standards of scientific rigour — handling medical conditions appropriately is part of that evolution.

Examiners working in therapeutic settings or addiction recovery programmes should coordinate with the treatment team to ensure that the polygraph examination supports rather than undermines the therapeutic relationship. Training programmes should include modules on medical conditions, as highlighted by research into examiner education requirements [34]Verified Autonomic Nervous System Dysfunction in Parkinson's Disease
Confirms ANS dysfunction affects 70-80% of PD patients and causes significant morbidity including cardiovascular, GI, and bladder symptoms.

Documenting PD-Related Findings

Reports involving PD examinees require additional documentation beyond standard polygraph report templates. The following elements should be included.

Medical History Section: Document the PD diagnosis date, current Hoehn & Yahr stage (if known), the diagnosing physician or movement disorder specialist, and the primary motor and non-motor symptoms reported. Note any prior autonomic testing results if available.

Medication Documentation: List all current medications with dosages and timing. Note the time of the most recent dose relative to the examination. Identify any medications known to affect polygraph-relevant physiology (anticholinergics, beta-blockers, dopamine agonists).

Pre-Test Observations: Describe the examinee's observed motor state at the time of testing, including tremor severity and distribution, presence of dyskinesias, and overall mobility. Note whether the examinee appeared to be in an "on" or "off" state.

Accommodation Record: Document all accommodations made, including sensor placement modifications, break frequency, extended inter-question intervals, and environmental adjustments.

Data Quality Assessment: For each channel, note whether the data was of sufficient quality for scoring. Identify specific artifacts attributed to PD and describe how they were managed. If any channel was excluded from scoring, explain the rationale.

Conclusion Caveats: Include a statement acknowledging the medical condition and any resulting limitations on the confidence level of the diagnostic opinion. Reference the Hoehn & Yahr stage and the degree of autonomic dysfunction as factors in the assessment. Reliable scoring systems validated in peer-reviewed research [30]Verified The Reliability of Polygraph Examiner Diagnosis of Truth and Deception
Foundational research demonstrating high inter-rater reliability for experienced examiners using structured scoring methods[32]Verified Resting and action tremor in Parkinson's disease: pathophysiological insights from long-term STN-DBS
Confirms DBS treatment for PD tremor and that resting tremor responded better to L-Dopa and STN-DBS than action tremor should be applied consistently, with any deviations clearly justified.